Simeprevir (Galexos — Janssen Inc.) indication: chronic hepatitis C genotype 1 infection

CADTH
Record ID 32015000212
English
Authors' recommendations: The Canadian Drug Expert Committee (CDEC) recommends that simeprevir, in combination with peginterferon alfa and ribavirin (PegIFN/ribavirin [RBV]), be listed for the treatment of chronic hepatitis C genotype 1 infection in adults with compensated liver disease, if clinical criteria and conditions are met.
Details
Project Status: Completed
Year Published: 2014
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Hepatitis C
  • Antiviral Agents
  • Hepatitis C, Chronic
  • Simeprevir
Contact
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name: requests@cadth.ca
Contact Email: requests@cadth.ca
Copyright: Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.